| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/21/2004 | EP1382333A2 Use of beta 3 adrenergic receptor agonists in the treatment of dysuria |
| 01/21/2004 | EP1381691A2 Method of determining a chemotherapeutic regimen based on ercc1 and ts expression |
| 01/21/2004 | EP1381684A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 01/21/2004 | EP1381681A1 The nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use |
| 01/21/2004 | EP1381678A2 Nucleic acid modification enzymes |
| 01/21/2004 | EP1381631A2 Human timp-1 antibodies |
| 01/21/2004 | EP1381629A2 RECEPTOR IN THE EDb FIBRONECTIN DOMAIN |
| 01/21/2004 | EP1381626A2 Human transporters and ion channels |
| 01/21/2004 | EP1381614A2 ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO 2,3-f]QUINOXALINE |
| 01/21/2004 | EP1381611A1 Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic |
| 01/21/2004 | EP1381607A1 Novel pyridine- and cyclohexenyl-comprising pyrrolobenzodiazepine-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists |
| 01/21/2004 | EP1381606A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors |
| 01/21/2004 | EP1381605A1 Mercaptoacetylamide derivatives, a process for their preparation and their use |
| 01/21/2004 | EP1381604A2 Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
| 01/21/2004 | EP1381603A2 Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands ) |
| 01/21/2004 | EP1381602A1 Heterocyclyldicarbamides as caspase inhibitors |
| 01/21/2004 | EP1381598A1 Novel tyrosine kinase inhibitors |
| 01/21/2004 | EP1381594A1 Urea compounds useful as anti-inflammatory agents |
| 01/21/2004 | EP1381592A1 1,4-disubstituted benzo-fused compounds |
| 01/21/2004 | EP1381590A1 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
| 01/21/2004 | EP1381431A1 Aromatase inhibition to enhance assisted reproduction |
| 01/21/2004 | EP1381397A2 Stabilisation of radiopharmaceutical compositions using a hydrophilic thioether or a hydrophilic 6-hydroxy chroman |
| 01/21/2004 | EP1381392A1 Synthetic catalyst for selective cleavage of protein and method for selective cleavage of protein using the same |
| 01/21/2004 | EP1381387A2 Use of stimulated peripheral blood mononuclear cells for treating cancerous diseases |
| 01/21/2004 | EP1381384A2 COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFa |
| 01/21/2004 | EP1381382A2 Methods and compositions for the treatment of diseases of the eye |
| 01/21/2004 | EP1381377A2 A composition including a platelet activating factor inhibitor and an antioxidant which interferes with the arachidonic acid cascade |
| 01/21/2004 | EP1381375A2 Oligonucleotide compositions and their use to induce differentiation of cells |
| 01/21/2004 | EP1381374A1 Veterinary compositions comprising avermectin-oxime derivatives and praziquantel |
| 01/21/2004 | EP1381372A2 Substituted tetracycline compounds as synergistic antifungal agents |
| 01/21/2004 | EP1381371A2 Hormone replacement therapy |
| 01/21/2004 | EP1381368A2 Compositions containing imidazotriazinone for nasal application |
| 01/21/2004 | EP1381365A1 Pyrrolidine sulfonamides |
| 01/21/2004 | EP1381363A1 Imidazo [1,2-a]-pyridine derivatives as mglur5 antagonists |
| 01/21/2004 | EP1381361A1 Combination therapy comprising glucose reabsorption inhibitors and ppar modulators |
| 01/21/2004 | EP1381359A1 Aurones as telomerase inhibitors |
| 01/21/2004 | EP1280799B1 Ortho-substituted anthranilic acid amides and their use as medicaments |
| 01/21/2004 | EP1242415B1 3-thiazol-4-yl-pyrrolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 01/21/2004 | EP1191942B1 Use of antileukoprotease for the treatment of endometriosis |
| 01/21/2004 | EP1131083B1 Use of growth hormone releasing compounds and their antagonists for the treatment of tumors |
| 01/21/2004 | EP0981366B1 Selective mmp inhibitors having reduced side-effects |
| 01/21/2004 | EP0942723B1 4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators |
| 01/21/2004 | EP0914124B1 ANTITHROMBOTIC AND ANTIATHEROGENIC PHARMACEUTICAL COMPOSITION INCLUDING A THIENOPYRIDINE DERIVATIVE AND AN HMG-CoA-REDUCTASE INHIBITOR |
| 01/21/2004 | EP0842276B1 Method for reproducing in vitro the rna-dependent rna polymerase and terminal nucleotidyl transferase activities encoded by hepatitis c virus (hcv) |
| 01/21/2004 | EP0727998B1 Oxazoles for treating cytokine mediated diseases |
| 01/21/2004 | CN1469877A Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament |
| 01/21/2004 | CN1469875A Pyrazole compounds useful as protein kinase inhibitors |
| 01/21/2004 | CN1469874A Pyrazole compounds useful as protein kinase inhibitors |
| 01/21/2004 | CN1469872A A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidine-1-yl)ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b] thiophene hydrochloride |
| 01/21/2004 | CN1469871A Substituted dipeptides as growth hormone secretagogues |
| 01/21/2004 | CN1469867A Novel phenylalanine derivatives |
| 01/21/2004 | CN1469756A Novel drugs for liver diseases |
| 01/21/2004 | CN1469749A Use of antiprogestins for the induction of apoptosis in a cell |
| 01/21/2004 | CN1469748A Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors |
| 01/21/2004 | CN1469746A A retroviral immunotherapy |
| 01/21/2004 | CN1469745A Preventives and remedies for complications of diabetes |
| 01/21/2004 | CN1469744A Pharmaceutical compositions containing oxapenem-3-carboxylic acids |
| 01/21/2004 | CN1469739A Method for modulating bladder function |
| 01/21/2004 | CN1469733A Method for producing powdery formulations |
| 01/21/2004 | CN1468615A Snore-eliminating health tea |
| 01/21/2004 | CN1468594A Composition containing at least one oxidative sensitive hydrophilic active ingredient through at least one maleic anhydride copolymer stabilization |
| 01/21/2004 | CN1135236C 5-membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists |
| 01/21/2004 | CN1135232C Piperazino derivatives as neurokinin antafonists |
| 01/21/2004 | CN1135111C Anti SARS Chinese herb medicine decoction |
| 01/20/2004 | US6680424 Modified proteinase inhibitors |
| 01/20/2004 | US6680375 Antibody for use in the diagnosis, treatment and prevention of bone disorders and cancer |
| 01/20/2004 | US6680341 Stable pharmaceutical formulation comprising a HMG-CoA reductase inhibitor |
| 01/20/2004 | US6680333 Imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them |
| 01/20/2004 | US6680330 Rapamycin dialdehydes |
| 01/20/2004 | US6680329 N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants |
| 01/20/2004 | US6680328 Cholinergic ligands of nicotinic acetyl choline receptors for treatment of central nervous system disorders, smooth muscle contraction disorders, endocrine diseases/disorders, neurodegeneration, inflammation, pain, and drug withdrawal |
| 01/20/2004 | US6680326 Antitumor agents; anticancer agents |
| 01/20/2004 | US6680320 Urokinase inhibitors |
| 01/20/2004 | US6680318 Piperazinomethylbenzamides as delta-opioid receptor agonists |
| 01/20/2004 | US6680317 N-(phenyl)-n*-(2-hydroxy-3-aminosulfonylphenyl)guanidine derivatives; chemokine inhibitors; respiratory, cardiovascular, rheumatic, brain, and nervous system disorders |
| 01/20/2004 | US6680314 Azacyclooctane and heptane derivatives, their preparation and use in therapy |
| 01/20/2004 | US6680309 Administering hypocalcemic hydroxyvitamin d compound having ahydrocarbon moiety at the c-24 position as anticarcinogenic agent |
| 01/20/2004 | US6680306 Method for enhancing the effectiveness of cancer therapies |
| 01/20/2004 | US6680293 Prevention of membrane formation; obtain cell tissue, incubate with inhibitory collagen, monitor membrane formation |
| 01/20/2004 | US6680198 Engraftable human neural stem cells |
| 01/20/2004 | US6680173 Diagnosis of tauopathies |
| 01/20/2004 | US6680171 Drug screening, genetic engineering |
| 01/20/2004 | CA2303498C Dioxocyclopentyl hydroxamic acids |
| 01/20/2004 | CA2274621C New nitrone derivatives, their preparation method and pharmaceutical compositions comprising them |
| 01/20/2004 | CA2273181C 3-aryl-2-(1-substituted-4-piperidinyl)-1(1-di)oxo-3h-benzo[d]-isothiazole derivatives, their preparation and their use as modulators of neurotransmitter function |
| 01/20/2004 | CA2258501C Vegetable extract, method for preparation thereof and its applications in human and veterinary medicine |
| 01/15/2004 | WO2004005549A1 Method of estimating effect of interferon |
| 01/15/2004 | WO2004005547A2 Method for identifying hypersensitive site consensus sequences |
| 01/15/2004 | WO2004005538A1 Method of screening anticancer agent |
| 01/15/2004 | WO2004005314A1 ESTRIENO[3,2-b]/[3,4-c]PYRROLE DERIVATIVES USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS |
| 01/15/2004 | WO2004005313A2 Hybrid molecules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules |
| 01/15/2004 | WO2004005296A1 Novel derivative of flavone c-glycoside and composition containing the same |
| 01/15/2004 | WO2004005295A1 Novel tricyclic spiropiperidines or spiropyrrolidines |
| 01/15/2004 | WO2004005293A2 N-aryl diazaspiracyclic compounds and methods of preparation and use thereof |
| 01/15/2004 | WO2004005286A2 Viral inhibitors |
| 01/15/2004 | WO2004005281A1 Inhibitors of tyrosine kinases |
| 01/15/2004 | WO2004005277A1 Novel compunds, pharmaceutical compositions containing same, and methods of use for same |
| 01/15/2004 | WO2004005276A1 Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives |
| 01/15/2004 | WO2004005266A1 Oxazole derivatives and their use as insulin sensitizers |
| 01/15/2004 | WO2004005265A1 Quinazoline derivatives |